Layik Hama

Dr. Layik Hama

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2019 in Journal of Open Source Software
Verified
Journal Article
Open access
PDF file
MMMalcolm Morgan
Malcolm Morgan
MYMarcus Young
Marcus Young
RLRobin Lovelace
Robin Lovelace
LHLayik Hama
Layik Hama
Opentripplanner provides functions that enable multi-modal routing in R. It provides an interface to the OpenTripPlanner (OTP) Java routing service, which allows calculation of routes on large transport networks, locally or via calls to a remote server. The package contains three groups of functions for: (1) setting up and managing a local instance of OTP; (2) connecting to OTP locally or remotely; and (3) sending requests to the OTP API and importing the results and converting them into appropriate classes for further analysis.

16 January 2019 in Journal of Open Source Software
Verified
Journal Article
Open access
PDF file
RLR Lovelace
R Lovelace
MMM Morgan
M Morgan
LHLayik Hama
Layik Hama
MPM Padgham
M Padgham
Stats19 provides functions for downloading and formatting road crash data. Specifically, it enables access to the UK's official road traffic casualty database, STATS19 (the name comes from the form used by the police to record car crashes and other incidents resulting in casualties on the roads). Finding, reading-in and formatting the data for research can be a time consuming process subject to human error, leading to previous (incomplete) attempts to facilitate the processes with open source software (Lovelace & Ellison, In press). stats19 speeds-up these data access and cleaning stages by streamlining the work into 3 stages:

30 August 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAAseel S Abuzour
Aseel S Abuzour
SWSamantha A. Wilson
Samantha A. Wilson
AWAlan A. Woodall
Alan A. Woodall
FMFrances Susanne Mair
Frances Susanne Mair
ACAndrew Clegg
Andrew Clegg
LWLauren E. Walker
Lauren E. Walker
Introduction: Structured medication reviews (SMRs), introduced in the United Kingdom (UK) in 2020, aim to enhance shared decision-making in medication optimisation, particularly for patients with multimorbidity and polypharmacy. Despite its potential, there is limited empirical evidence on the implementation of SMRs, and the challenges faced in the process. This study is part of a larger DynAIRx (Artificial Intelligence for dynamic prescribing optimisation and care integration in multimorbidity) project which aims to introduce Artificial Intelligence (AI) to SMRs and develop machine learning models and visualisation tools for patients with multimorbidity. Here, we explore how SMRs are currently undertaken and what barriers are experienced by those involved in them. Methods: Qualitative focus groups and semi-structured interviews took place between 2022–2023. Six focus groups were conducted with doctors, pharmacists and clinical pharmacologists (n = 21), and three patient focus groups with patients with multimorbidity (n = 13). Five semi-structured interviews were held with 2 pharmacists, 1 trainee doctor, 1 policy-maker and 1 psychiatrist. Transcripts were analysed using thematic analysis. Results: Two key themes limiting the effectiveness of SMRs in clinical practice were identified: ‘Medication Reviews in Practice’ and ‘Medication-related Challenges’. Participants noted limitations to the efficient and effectiveness of SMRs in practice including the scarcity of digital tools for identifying and prioritising patients for SMRs; organisational and patient-related challenges in inviting patients for SMRs and ensuring they attend; the time-intensive nature of SMRs, the need for multiple appointments and shared decision-making; the impact of the healthcare context on SMR delivery; poor communication and data sharing issues between primary and secondary care; difficulties in managing mental health medications and specific challenges associated with anticholinergic medication. Conclusion: SMRs are complex, time consuming and medication optimisation may require multiple follow-up appointments to enable a comprehensive review. There is a need for a prescribing support system to identify, prioritise and reduce the time needed to understand the patient journey when dealing with large volumes of disparate clinical information in electronic health records. However, monitoring the effects of medication optimisation changes with a feedback loop can be challenging to establish and maintain using current electronic health record systems.

8 January 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
AAAseel S Abuzour
Aseel S Abuzour
SWSamantha A Wilson
Samantha A Wilson
AWAlan A Woodall
Alan A Woodall
FMFrances Susanne Mair
Frances Susanne Mair
AAAsra Aslam
Asra Aslam
LWLauren E Walker
Lauren E Walker
Background: Structured medication reviews (SMRs) are an essential component of medication optimization, especially for patients with multimorbidity and polypharmacy. However, the process remains challenging due to the complexities of patient data, time constraints, and the need for coordination among health care professionals (HCPs). This study explores HCPs’ perspectives on the integration of artificial intelligence (AI)–assisted tools to enhance the SMR process, with a focus on the potential benefits of and barriers to adoption. Objective: This study aims to identify the key user requirements for AI-assisted tools to improve the efficiency and effectiveness of SMRs, specifically for patients with multimorbidity, complex polypharmacy, and frailty. Methods: A qualitative study was conducted involving focus groups and semistructured interviews with HCPs and patients in the United Kingdom. Participants included physicians, pharmacists, clinical pharmacologists, psychiatrists from primary and secondary care, a policy maker, and patients with multimorbidity. Data were analyzed using a hybrid inductive and deductive thematic analysis approach to identify themes related to AI-assisted tool functionality, workflow integration, user-interface visualization, and usability in the SMR process. Results: Four major themes emerged from the analysis: innovative AI potential, optimizing electronic patient record visualization, functionality of the AI tool for SMRs, and facilitators of and barriers to AI tool implementation. HCPs identified the potential of AI to support patient identification and prioritizing those at risk of medication-related harm. AI-assisted tools were viewed as essential in detecting prescribing gaps, drug interactions, and patient risk trajectories over time. Participants emphasized the importance of presenting patient data in an intuitive format, with a patient interface for shared decision-making. Suggestions included color-coding blood results, highlighting critical medication reviews, and providing timelines of patient medical histories. HCPs stressed the need for AI tools to integrate seamlessly with existing electronic patient record systems and provide actionable insights without overwhelming users with excessive notifications or “pop-up” alerts. Factors influencing the uptake of AI-assisted tools included the need for user-friendly design, evidence of tool effectiveness (though some were skeptical about the predictive accuracy of AI models), and addressing concerns around digital exclusion. Conclusions: The findings highlight the potential for AI-assisted tools to streamline and optimize the SMR process, particularly for patients with multimorbidity and complex polypharmacy. However, successful implementation depends on addressing concerns related to workflow integration, user acceptance, and evidence of effectiveness. User-centered design is crucial to ensure that AI-assisted tools support HCPs in delivering high-quality, patient-centered care while minimizing cognitive overload and alert fatigue.

Verified
Journal Article
Open access
PDF file
RBRoger Beecham
Roger Beecham
JDJason Dykes
Jason Dykes
LHLayik Hama
Layik Hama
NLNik Lomax
Nik Lomax
Recent analysis of area-level COVID-19 cases data attempts to grapple with a challenge familiar to geovisualization: how to capture the development of the virus, whilst supporting analysis across geographic areas? We present several glyphmap designs for addressing this challenge applied to local authority data in England whereby charts displaying multiple aspects related to the pandemic are given a geographic arrangement. These graphics are visually complex, with clutter, occlusion and salience bias an inevitable consequence. We develop a framework for describing and validating the graphics against data and design requirements. Together with an observational data analysis, this framework is used to evaluate our designs, relating them to particular data analysis needs based on the usefulness of the structure they expose. Our designs, documented in an accompanying code repository, attend to common difficulties in geovisualization design and could transfer to contexts outside of the UK and to phenomena beyond the pandemic.

19 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
AAAseel S Abuzour
Aseel S Abuzour
SWSamantha A Wilson
Samantha A Wilson
AWAlan A Woodall
Alan A Woodall
FMFrances Susanne Mair
Frances Susanne Mair
ACAndrew Clegg
Andrew Clegg
LWLauren E Walker
Lauren E Walker
Introduction Structured medication reviews (SMRs), introduced in the United Kingdom (UK) in 2020, aim to enhance shared decision-making in medication optimisation, particularly for patients with multimorbidity and polypharmacy. Despite its potential, there is limited empirical evidence on the implementation of SMRs, and the challenges faced in the process. This study is part of a larger DynAIRx (Artificial Intelligence for dynamic prescribing optimisation and care integration in multimorbidity) project which aims to introduce Artificial Intelligence (AI) to SMRs and develop machine learning models and visualisation tools for patients with multimorbidity. Here, we explore how SMRs are currently undertaken and what barriers are experienced by those involved in them. Methods Qualitative focus groups and semi-structured interviews took place between 2022-2023. Nine focus groups were conducted with doctors, pharmacists and clinical pharmacologists (n=21), and three patient focus groups with patients at high-risk of rapidly worsening health from multimorbidity (n=13). Five semi-structured interviews were held with 2 pharmacists, 1 trainee doctor, 1 policy-maker and 1 psychiatrist. Transcripts were analysed using a thematic approach. Results Two key themes limiting the effectiveness of SMRs in clinical practice were identified: ‘Medication Reviews in Practice’ and ‘Medication-related Challenges’. Participants noted limitations to the efficient and effectiveness of SMRs in practice including the scarcity of digital tools for identifying and prioritising patients for SMRs; organisational and patient-related challenges in inviting patients for SMRs and ensuring they attend; the time-intensive nature of SMRs, the need for multiple appointments and shared decision-making; the impact of the healthcare context on SMR delivery; poor communication and data sharing issues between primary and secondary care; difficulties in managing mental health medications and specific challenges associated with anticholinergic medication. Conclusion SMRs are complex, time consuming and medication optimisation may require multiple follow-up appointments to enable a comprehensive review. There is a need for a prescribing support system to identify, prioritise and reduce the time needed to understand the patient journey when dealing with large volumes of disparate clinical information in electronic health records. However, monitoring the effects of medication optimisation changes with a feedback loop can be challenging to establish and maintain using current electronic health record systems.